Annual report pursuant to Section 13 and 15(d)

Note 2 - Significant Accounting Policies and Basis of Presentation (Details Textual)

v3.19.1
Note 2 - Significant Accounting Policies and Basis of Presentation (Details Textual) - USD ($)
shares in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Jan. 01, 2019
Cost Reimbursements from SBIR Grant as Offset to Research and Development Expenses $ 538,000 $ 41,000  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12.6 10.2  
Accounting Standards Update 2016-02 [Member] | Subsequent Event [Member]      
Operating Lease, Right-of-Use Asset     $ 50,000
Operating Lease, Liability, Total     $ 75,000